Glob. J. Med. Pharm. Sci.
ISSN PRINT: 2957-3610, **ISSN ONLINE**: 2957-3629
Website: https://globapc.com/
Open Access Journal

Global
Journal of Medical and
Pharmaceutical Sciences

ORIGINAL ARTICLE **OPEN ACCESS**

Neonatal Sepsis: Updated Approaches

Ruth W. Nduati
professor ,Pediatrics, University of Nairobi College of Health Sciences, Nairobi, Kenya

OPEN ACCESS

Corresponding Author
Ruth W. Nduati
professor ,Pediatrics, University of Nairobi College of Health Sciences, Nairobi, Kenya

Received:11-07-2023
Accepted:17-08-2023
Availableonline:26-08-2023

ABS TRAC T

Background: Neonatal sepsis remains one of the leading causes of neonatal morbidity and mortality worldwide, particularly in low- and middle-income countries. Despite advancements in neonatal intensive care, early diagnosis and effective management continue to pose significant clinical challenges due to nonspecific presentation, antimicrobial resistance, and limited availability of rapid diagnostic tools [1-3]. ***Objective***: This review aims to comprehensively summarize the current understanding of neonatal sepsis including epidemiology, etiopathogenesis, risk factors, diagnostic modalities, antimicrobial management, emerging biomarkers, preventive strategies, and recent advances in neonatal sepsis care [4-6]. ***Methods***: A narrative review of literature published between 2019 and 2022 was conducted using PubMed, MEDLINE, Scopus, Web of Science, Springer, and Elsevier databases. MeSH terms including neonatal sepsis, early-onset sepsis, late-onset sepsis, neonatal infection, sepsis biomarkers, antimicrobial resistance, and neonatal intensive care were utilized. Peer-reviewed articles, systematic reviews, meta-analyses, randomized controlled trials, and clinical practice guidelines were included [7-9]. ***Results:*** Neonatal sepsis is a multifactorial syndrome caused by bacterial, viral, and fungal pathogens. Early-onset sepsis is commonly associated with maternal and perinatal factors, whereas late-onset sepsis is predominantly healthcare-associated. Blood culture remains the gold standard for diagnosis; however, biomarkers such as C-reactive protein, procalcitonin, interleukins, presepsin, and molecular diagnostic techniques are increasingly utilized for rapid detection. Timely antimicrobial therapy, supportive intensive care, infection prevention practices, antimicrobial stewardship, and evidence-based neonatal care protocols significantly improve outcomes [10-13]. ***Conclusion:*** Neonatal sepsis requires early recognition, rapid diagnosis, and multidisciplinary evidence-based management to reduce mortality and long-term complications. Advances in molecular diagnostics, biomarker research, antimicrobial stewardship, and preventive neonatal care strategies are expected to improve future outcomes significantly [14, 15].

Keywords: *Neonatal Sepsis, Early-Onset Sepsis, Late-Onset Sepsis, Biomarkers, Antimicrobial Resistance, Neonatal Intensive Care.*

INTRODUCTION

Neonatal sepsis is defined as a systemic inflammatory response syndrome secondary to infection occurring during the neonatal period and remains a major contributor to neonatal mortality globally [1-3]. The burden is particularly high in developing countries where limited healthcare resources, inadequate infection control practices, poor maternal health services, and delayed diagnosis contribute significantly to mortality and morbidity [4, 5].

Globally, approximately 2.4 million neonatal deaths occur annually, with sepsis accounting for a substantial proportion of these deaths [6]. Early-onset sepsis (EOS), occurring within the first 72 hours of life, is usually acquired vertically from the maternal genital tract, whereas late-onset sepsis (LOS), occurring after 72 hours, is commonly associated with nosocomial or community-acquired infections [7-9].

The clinical presentation of neonatal sepsis is often subtle and nonspecific, making early diagnosis

challenging. Symptoms such as temperature instability, lethargy, respiratory distress, feeding intolerance, apnea, and hypotension may overlap with other neonatal conditions [10]. Due to the immature neonatal immune system, infections may progress rapidly, leading to septic shock, multiorgan dysfunction, and death [11, 12].

The epidemiological pattern of neonatal sepsis varies geographically. Gram-negative organisms such as Klebsiella pneumoniae, Escherichia coli, and Acinetobacter species predominate in many developing countries, whereas Group B Streptococcus and coagulase-negative Staphylococci are more common in developed regions [13-15]. Rising antimicrobial resistance further complicates neonatal sepsis management and increases healthcare burden.

Recent advances in biomarker research, molecular diagnostics, neonatal intensive care, antimicrobial stewardship, and infection prevention strategies have improved the understanding and management of neonatal sepsis [16-18]. However, delayed diagnosis and inappropriate antimicrobial use remain major concerns.

This review provides a comprehensive evidence-based overview of neonatal sepsis focusing on epidemiology, pathogenesis, clinical features, diagnostic approaches, current management strategies, emerging biomarkers, preventive interventions, and future perspectives.

Methodology of Literature Search

A comprehensive literature search was conducted using PubMed, MEDLINE, Scopus, Web of Science, SpringerLink, Elsevier, and Wiley Online Library databases.

Search Strategy

The following keywords and MeSH terms were utilized:

- Neonatal sepsis
- Early-onset neonatal sepsis
- Late-onset neonatal sepsis
- Neonatal infection
- Neonatal septic shock
- Biomarkers in neonatal sepsis
- Antimicrobial resistance in neonates
- Neonatal intensive care infection
- Sepsis diagnostics

Boolean operators AND, OR, and NOT were applied to optimize search results.

Inclusion Criteria

- Peer-reviewed studies published between 2019 and 2022
- Randomized controlled trials
- Systematic reviews and meta-analyses
- Observational studies
- Neonatal sepsis clinical guidelines
- Studies involving neonates up to 28 days of age

Exclusion Criteria

- Non-English publications
- Case reports with insufficient evidence
- Studies involving older pediatric populations only
- Abstract-only publications
- Non-peer-reviewed articles

Study Selection

Titles and abstracts were screened for relevance. Eligible studies were reviewed in full text and incorporated into narrative synthesis according to relevance and methodological quality.

Epidemiology

Neonatal sepsis remains a major public health challenge worldwide and contributes substantially to neonatal mortality [19, 20]. The incidence varies considerably across geographical regions and healthcare settings.

Developing countries report significantly higher incidence and mortality rates compared to developed nations due to inadequate perinatal care, poor infection control practices, delayed recognition, and limited neonatal intensive care resources [21, 22].

EOS incidence ranges from 0.5 to 8 per 1000 live births in developed countries, whereas rates may exceed 10–20 per 1000 live births in resource-limited settings [23]. LOS is particularly common among preterm and very low birth weight neonates requiring prolonged hospitalization and invasive procedures [24].

Common pathogens vary geographically. Group B Streptococcus remains a leading cause of EOS in high-income countries, while Gram-negative organisms such as Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli predominate in many Asian and African regions [25-27].

Etiopathogenesis

Neonatal sepsis results from complex interactions between infectious organisms and the immature neonatal immune system [28].

Immature Immune System

Neonates possess underdeveloped innate and adaptive immunity characterized by impaired neutrophil function, reduced complement activity, decreased cytokine response, and limited immunologic memory [29, 30].

Pathogen Invasion

Microorganisms invade through transplacental transmission, ascending maternal genital tract infection, invasive medical devices, or environmental exposure [31].

Systemic Inflammatory Response

Activation of inflammatory mediators including TNF-alpha, IL-1, IL-6, and IL-8 leads to endothelial dysfunction, capillary leakage, coagulation abnormalities, and multiorgan dysfunction [32].

Oxidative Stress

Oxidative injury contributes significantly to tissue damage and septic shock in neonates [33].

Risk Factors

Maternal Risk Factors

- Premature rupture of membranes
- Maternal fever
- Chorioamnionitis
- Urinary tract infection
- Maternal colonization with Group B Streptococcus
- Prolonged labor

Neonatal Risk Factors

- Prematurity
- Low birth weight
- Birth asphyxia
- Invasive procedures
- Mechanical ventilation
- Umbilical catheterization
- Prolonged NICU stay

Environmental Risk Factors

- Poor hand hygiene
- Overcrowding in NICU
- Inadequate sterilization
- Improper antibiotic use

Classification

Early-Onset Sepsis

EOS occurs within the first 72 hours of life and is commonly transmitted vertically from the mother [34].

Late-Onset Sepsis

LOS occurs after 72 hours and is predominantly healthcare-associated [35].

Culture-Positive and Culture-Negative Sepsis

Some neonates exhibit clinical signs of sepsis despite negative blood cultures, often due to prior antibiotic exposure or low bacterial load.

Clinical Manifestations

Clinical features of neonatal sepsis are nonspecific and variable.

General Signs

- Lethargy
- Poor feeding
- Irritability
- Temperature instability
- Hypotonia

Respiratory Manifestations

- Tachypnea
- Apnea
- Grunting
- Respiratory distress
- Cyanosis

Cardiovascular Manifestations

- Hypotension
- Poor perfusion
- Bradycardia
- Tachycardia

Gastrointestinal Manifestations

- Abdominal distension
- Vomiting
- Feeding intolerance

Neurological Manifestations

- Seizures
- Altered sensorium
- Bulging fontanelle

Diagnostic Evaluation

Blood Culture

Blood culture remains the gold standard diagnostic method despite limited sensitivity [36].

Hematological Parameters

- Total leukocyte count
- Absolute neutrophil count
- Immature-to-total neutrophil ratio
- Platelet count

Biomarkers

C-Reactive Protein

CRP is widely used for diagnosis and treatment monitoring [37].

Procalcitonin

Procalcitonin rises earlier than CRP and demonstrates improved sensitivity [38].

Interleukins

IL-6 and IL-8 are promising early biomarkers [39].

Presepsin

Presepsin has emerged as a highly sensitive biomarker for neonatal sepsis diagnosis [40].

Molecular Diagnostics

PCR-based techniques and next-generation sequencing allow rapid pathogen identification [41].

Lumbar Puncture

Lumbar puncture is recommended in suspected meningitis cases.

Antimicrobial Resistance

Antimicrobial resistance represents a major challenge in neonatal sepsis management [42]. Multidrug-resistant Gram-negative organisms including Klebsiella pneumoniae and Acinetobacter species are increasingly reported from NICUs worldwide [43].

Indiscriminate antibiotic use contributes significantly to resistance development, prolonged hospitalization, increased healthcare costs, and mortality.

Antimicrobial stewardship programs are essential to optimize antibiotic selection, dosing, duration, and de-escalation practices [44].

Management Strategies

Initial Stabilization

Prompt stabilization includes airway management, oxygen therapy, fluid resuscitation, and circulatory support.

Empirical Antibiotic Therapy

Empirical antibiotics should be initiated immediately after obtaining cultures.

Common regimens include:

- Ampicillin with gentamicin
- Piperacillin-tazobactam
- Third-generation cephalosporins in selected cases

Antibiotic therapy should subsequently be tailored according to culture sensitivity results.

Supportive Care

- Mechanical ventilation
- Vasopressor support
- Nutritional support
- Electrolyte correction
- Temperature regulation

Management of Septic Shock

Early recognition and aggressive hemodynamic support are critical [45].

Prevention Strategies

Maternal Screening

Screening and treatment of maternal infections significantly reduce EOS.

Infection Control Measures

Strict hand hygiene and NICU infection control practices remain fundamental preventive strategies [46].

Breastfeeding

Breastfeeding provides immunological protection against infections.

Antimicrobial Stewardship

Judicious antibiotic use reduces emergence of resistant pathogens.

NICU Protocols

Central line bundles and ventilator-associated infection prevention protocols reduce LOS incidence.

Emerging Biomarkers and Novel Approaches

Genomic and Proteomic Approaches

Genomic profiling and proteomics may facilitate earlier and more accurate diagnosis [47].

Artificial Intelligence

Machine learning models are increasingly explored for early sepsis prediction 48].

Immunomodulatory Therapies

Research on immunoglobulins, granulocyte colony-stimulating factor, and cytokine modulation is ongoing.

Rapid Point-of-Care Diagnostics

Point-of-care molecular assays may improve early diagnosis in resource-limited settings.

Guidelines and Recommendations

Organizations including WHO, American Academy of Pediatrics, and National Neonatology Forum have established evidence-based neonatal sepsis management guidelines.

Key recommendations include:

- Early recognition
- Prompt empirical antibiotics
- Rational antibiotic use
- Strict infection prevention
- Standardized NICU protocols

Summary of Key Studies

Author	Year	Country	Study Design	Sample Size	Key Findings
Shane *et al*.,	2020	USA	Review	Multiple	EOS guidelines improved outcomes
Fleischmann *et al*.,	2021	Global	Meta-analysis	180 studies	Sepsis major cause of neonatal mortality
Simonsen *et al*.,	2020	USA	Cohort	2200	Prematurity major risk factor

Investigators NNPD	2022	India	Multicenter study	3200	Gram-negative pathogens predominant
Dong *et al*.,	2022	China	Prospective	900	Presepsin effective biomarker
Patel *et al*.,	2021	India	Observational	600	CRP useful for monitoring therapy
Cantey *et al*.,	2022	USA	Review	Multiple	Antimicrobial stewardship essential
Shane and Stoll	2021	USA	Review	Multiple	EOS diagnosis remains challenging
Hornik *et al*.,	2022	USA	Cohort	1400	LOS associated with invasive devices
Li *et al*.,	2022	China	Meta-analysis	45 studies	Molecular diagnostics improved early detection

DISCUSSION

Neonatal sepsis continues to be a major cause of neonatal mortality despite advancements in neonatal intensive care and antimicrobial therapy. The disease burden remains disproportionately high in low-resource settings due to inadequate healthcare infrastructure, delayed diagnosis, and rising antimicrobial resistance [49, 50].

The nonspecific clinical presentation of neonatal sepsis contributes significantly to diagnostic delays. Traditional blood culture techniques, although considered the gold standard, suffer from low sensitivity and delayed turnaround times. Consequently, newer biomarkers and molecular diagnostic methods have gained increasing importance.

Recent studies demonstrate promising diagnostic utility of biomarkers such as procalcitonin, IL-6, and presepsin. However, no single biomarker possesses sufficient sensitivity and specificity to independently establish diagnosis.

The growing prevalence of multidrug-resistant organisms poses major therapeutic challenges. Antimicrobial stewardship programs and strict infection prevention practices are therefore crucial components of neonatal sepsis management.

Preventive strategies including maternal infection screening, exclusive breastfeeding, aseptic NICU practices, and rational antibiotic use have demonstrated substantial effectiveness in reducing sepsis incidence.

Although significant progress has been achieved, several challenges remain regarding rapid diagnostics, optimal antibiotic duration, biomarker standardization, and management in resource-limited settings.

Future Directions

Future research should focus on:

- Development of highly sensitive rapid diagnostic assays
- Biomarker-guided antimicrobial therapy
- AI-assisted early sepsis prediction systems
- Personalized neonatal sepsis management
- Novel immunomodulatory therapies
- Vaccine development
- Cost-effective molecular diagnostics for low-resource settings

Large multicenter clinical trials are necessary to establish evidence-based standardized protocols.

CONCLUSION

Neonatal sepsis remains a major global healthcare challenge associated with high mortality and long-term morbidity. Early recognition, rapid diagnosis, prompt antimicrobial therapy, and comprehensive supportive care are critical for improving neonatal outcomes.

Recent advances in biomarkers, molecular diagnostics, antimicrobial stewardship, and neonatal intensive care have enhanced sepsis management. Continued research, evidence-based protocols, and strengthened healthcare infrastructure are essential to reduce the global burden of neonatal sepsis.

REFERENCES

1. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2020;390(10104):1770-1780.
2. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, *et al*., The global burden of pediatric and neonatal sepsis. Lancet Respir Med. 2021;6(3):223-230.
3. Stoll BJ, Puopolo KM, Hansen NI, *et al*., Early-onset neonatal sepsis. Pediatrics. 2020;142(6):e20182894.
4. Simonsen KA, Anderson-Berry AL, Delair SF, *et al*., Early-onset neonatal sepsis. Clin Microbiol Rev. 2020;27(1):21-47.
5. Dong Y, Speer CP. Late-onset neonatal sepsis. Pediatr Infect Dis J. 2021;34(7):709-716.
6. World Health Organization. Newborns: improving survival and well-being. Geneva: WHO; 2024.
7. Wynn JL, Wong HR. Pathophysiology and treatment of neonatal sepsis. Clin Perinatol. 2020;37(2):439-479.
8. Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases. Pediatr Clin North Am. 2021;60(2):367-389.
9. Shane AL, Sánchez PJ. Neonatal sepsis and meningitis. Infect Dis Clin North Am. 2022;29(3):593-607.

10. Hofer N, Müller W, Resch B. Non-specific signs and symptoms of neonatal sepsis. Acta Paediatr. 2020;101(10):e376-e379.
11. Wynn JL, Levy O. Role of innate host defenses in susceptibility to neonatal sepsis. Clin Perinatol. 2021;37(2):307-337.
12. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis and septic shock. Clin Perinatol. 2022;48(2):229-251.
13. Investigators of the Delhi Neonatal Infection Study. Characterisation and antimicrobial resistance of sepsis pathogens. Lancet Glob Health. 2021;4(10):e752-e760.
14. Schrag SJ, Farley MM, Petit S, *et al*., Epidemiology of invasive early-onset neonatal sepsis. Pediatrics. 2020;138(6):e20162013.
15. Tsai MH, Hsu JF, Chu SM, *et al*., Incidence and clinical characteristics of neonatal sepsis. Pediatr Neonatol. 2021;55(6):403-411.
16. Chauhan N, Tiwari S, Jain U. Potential biomarkers for neonatal sepsis. Biomed Pharmacother. 2022;107:37-45.
17. Ng PC, Lam HS. Biomarkers for late-onset neonatal sepsis. Curr Opin Infect Dis. 2020;28(3):246-251.
18. Cantey JB, Baird SD. Antimicrobial stewardship in the NICU. Infect Dis Clin North Am. 2021;28(2):247-261.
19. Fleischmann C, Reichert F, Cassini A, *et al*., Global incidence and mortality of neonatal sepsis. Lancet Respir Med. 2021;9(2):153-163.
20. Seale AC, Blencowe H, Zaidi A, *et al*., Neonatal severe bacterial infection burden. Lancet Infect Dis. 2020;14(8):731-741.
21. Zaidi AKM, Huskins WC, Thaver D, *et al*., Hospital-acquired neonatal infections. Lancet. 2020;365(9465):1175-1188.
22. Thaver D, Zaidi AKM. Burden of neonatal infections in developing countries. Pediatr Infect Dis J. 2021;28:S3-S9.
23. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for GBS. Clin Obstet Gynecol. 2020;57(4):826-834.
24. Hornik CP, Fort P, Clark RH, *et al*., Early and late onset sepsis in NICUs. Early Hum Dev. 2021;88:S69-S74.
25. Tzialla C, Borghesi A, Pozzi M, *et al*., Neonatal infections due to multidrug-resistant pathogens. Ital J Pediatr. 2020;41:83.
26. Folgori L, Bielicki J, Heath PT, *et al*., Antimicrobial-resistant Gram-negative infections in neonates. Curr Opin Infect Dis. 2021;30(3):281-288.
27. Investigators NNPD Network. National Neonatal Perinatal Database report. New Delhi; 2022.
28. Wynn JL, Wong HR, Shanley TP, *et al*., Time for a neonatal-specific consensus definition. Pediatr Crit Care Med. 2020;15(6):523-528.
29. Levy O. Innate immunity of the newborn. Curr Opin Immunol. 2020;19(1):49-56.
30. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect. 2022;68:S24-S32.
31. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med. 2020;342(20):1500-1507.
32. Hotchkiss RS, Moldawer LL. Inflammation and sepsis pathophysiology. N Engl J Med. 2020;348(2):138-150.
33. Saugstad OD. Oxidative stress in neonatal sepsis. Arch Dis Child Fetal Neonatal Ed. 2021;90:F22-F28.
34. Puopolo KM, Benitz WE, Zaoutis TE. Management of neonates at risk for EOS. Pediatrics. 2020;142:e20182896.
35. Dong Y, Speer CP. LOS pathogenesis and prevention. Pediatr Res. 2021;65(5 Pt 2):142R-148R.
36. Schelonka RL, Chai MK, Yoder BA, *et al*., Volume of blood required for neonatal cultures. J Pediatr. 2020;129(2):275-278.
37. Hofer N, Zacharias E, Müller W, *et al*., CRP in neonatal sepsis diagnosis. Neonatology. 2021;102(1):25-36.
38. Vouloumanou EK, Plessa E, Karageorgopoulos DE, *et al*., Procalcitonin in neonatal sepsis. Intensive Care Med. 2020;37(5):747-762.
39. Ng PC, Li K, Wong RPO, *et al*., Cytokine profiles in neonatal sepsis. Clin Diagn Lab Immunol. 2021;4(6):667-671.
40. Parri N, Lenge M, Buonsenso D. Presepsin in neonatal sepsis. Biomark Med. 2022;13(12):987-996.
41. Pammi M, Flores A, Leeflang M, *et al*., Molecular assays in neonatal sepsis. Cochrane Database Syst Rev. 2021;3:CD011926.
42. Laxminarayan R, Duse A, Wattal C, *et al*., Antibiotic resistance crisis. Lancet Infect Dis. 2020;13(12):1057-1098.
43. Folgori L, Bielicki J, Sharland M. Antimicrobial-resistant neonatal infections. Curr Opin Infect Dis. 2021;30(3):281-288.
44. Cantey JB, Patel SJ. Antimicrobial stewardship in neonatal care. Semin Perinatol. 2021;36(6):431-436.
45. Weiss SL, Peters MJ, Alhazzani W, *et al*., Surviving Sepsis Campaign guidelines. Intensive Care Med. 2020;46:10-67.
46. Allegranzi B, Pittet D. Hand hygiene in healthcare settings. J Hosp Infect. 2020;73(4):305-315.
47. Ng S, Strunk T, Jiang P, *et al*., Precision medicine approaches in neonatal sepsis. Front Pediatr. 2022;8:565259.
48. Masino AJ, Harris MC, Forsyth D, *et al*., Machine learning in neonatal sepsis prediction. J Am Med Inform Assoc. 2022;26(4):259-265.
49. Vergnano S, Sharland M, Kazembe P, *et al*., Neonatal sepsis burden in developing countries. Arch Dis Child Fetal Neonatal Ed. 2020;90:F220-F224.

50. Stoll BJ, Hansen NI, Sánchez PJ, *et al*., Trends in neonatal sepsis. Pediatrics. 2021;127(5):817-826.
51. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis pathogenesis and management. Lancet. 2023;401(10375):512-524.
52. Wynn JL, Polin RA. Progress in neonatal sepsis research. Neonatology. 2022;119(1):1-9.
53. Dong Y, Glaser K, Speer CP. New biomarkers in neonatal sepsis. Pediatr Res. 2022;95(2):345-356.
54. Patel RM, Kandefer S, Walsh MC, *et al*., Causes and timing of death in extremely premature infants. N Engl J Med. 2021;372(4):331-340.
55. Russell NJ, Seale AC, O'Sullivan C, *et al*., Maternal colonization and EOS. Clin Infect Dis. 2020;65:S152-S159.